US 11596671
Gene therapy of hemophilia B using viral vectors encoding recombinant fix variants with increased expression
granted A61KA61K38/36A61K48/005
Quick answer
US patent 11596671 (Gene therapy of hemophilia B using viral vectors encoding recombinant fix variants with increased expression) held by Takeda Pharmaceutical Company Limited expires Mon Mar 02 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Takeda Pharmaceutical Company Limited
- Grant date
- Tue Mar 07 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Mar 02 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 16
- CPC classes
- A61K, A61K38/36, A61K48/005, A61K48/0058, A61K48/0066